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ABSTRACT 
Astrocytomas are the most common glioma, accounting for about half of all primary brain 
and spinal cord tumors. Malignancy in these tumors ranges from the least aggressive 
pilocytic astrocytoma (WHO grade 1) to the most aggressive glioblastoma (WHO grade 4). 
Molecular biomarkers or signatures—i.e., patterns of gene or protein expression that can 
reliably distinguish between each grade and provide insight into the underlying molecular 
events associated with tumor progression—have not yet been well established for 
astrocytomas. To identify candidate biomarkers and characterize genetic and molecular 
mechanisms driving glioma development and progression, we performed a meta-analysis of 
publicly available microarray gene expression datasets, comprising 432 tumor samples from 
all four grades and 28 non-tumor samples.  
We first applied a consensus preprocessing method to raw microarray data to reduce bias 
introduced by different laboratories. Using DIRAC, a network-based classification approach 
previously developed in our lab, we were able to effectively differentiate tumor grades with 
an average accuracy of 87%. Additionally, we derived 46 specific transcriptional changes 
that are associated with astrocytoma progression; of the 46 genes, 27 were consistently 
upregulated and 19 were downregulated in the progression sequence.  
Notably, we discovered a histology-independent classifier, a network using erythropoietin to 
mediate neuroprotection through NF-kB (EPONFKB), consisting of 11 genes and predictive 
of survival in high grade astrocytoma (HGA) patients. This network is known for its roles in 
neuronal development and is capable of classifying HGAs into previously unrecognized 
subtypes. It has proven to be a more significant survival predictor (P = 2.4e-8) than histology-
based grading (P = 2.2e-6). 
With our network signatures associated with each grade and our progression-associated 
genes, we hope to increase the understanding of molecular mechanisms leading to brain 
cancer development, maintenance and progression. With the identification of the EPONFKB 
network as a novel prognostic factor, we hope to move tumor diagnosis and prognosis toward 
a more quantitative realm. 
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CHAPTER 1 
INTRODUCTION 
Astrocytomas are the most common gliomas, originating in star-shaped brain cells called 
astrocytes [1]. The conventional histopathologic diagnosis scheme is based on the World 
Health Organization (WHO) grading system, which assigns a grade from 1 (least aggressive, 
also called pilocytic astrocytomas) to 4 (most aggressive, also called glioblastoma) [2]. 
According to the WHO scale, major distinguishing hispathological features between different 
grades include growth rate of cells, rate of angiogenesis, and presence of necrosis [2].  
 
Tumor typing and grading that rely completely on the WHO system may be insufficient due 
to the subjective nature of pathological diagnosis [3]. Histological variability is commonly 
present within the same tumor, whereby characteristics defined by WHO may only offer an 
oversimplified representation of the actual tumor features [3, 4]. As a result, diagnostic 
accuracy and reproducibility are jeopardized, giving rise to significant inter-observer 
variability [5, 6]. 
 
However, accurate diagnosis is required for adequate treatment and to assess prognosis for 
patients. While piloctyic tumors (G1) are easily removed through surgery, for low-grade 
tumors (G2) and higher, the chance of recurrence increases while the survival rate diminishes; 
anaplastic astrocytoma (G3) and glioblastoma (G4 or GBM) patients have dim prognostic 
prospects, with GBM few patients surviving more than 12 months after diagnosis [7, 8] .  
 
Due to these reasons, many research studies have devoted their efforts to finding the genetic 
and molecular differences associated with astrocytoma patients. Most of these studies limited 
their focus to one or some of the grades [9-13]. Our study aimed to conduct a meta-analysis 
on microarray expression profiles of astrocytoma patients of various grades, and investigated 
the genetic and biological mechanisms implicated in the phenotypic differences. We 
achieved our goals through both network-based and gene-based approaches; firstly, networks 
that could best distinguish astrocytoma patients were analyzed followed by an investigation 
on the individual gene sets changing consistently with progression. Lastly, a network with 
prognostic value was found with available survival information. 
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A network-based classification method, Differential Rank Conservation (DIRAC) allowed us 
to identify differentially expressed networks (DENs) that revealed statistically robust 
differences between different astrocytoma tumors, leading to highly accurate classification of 
histologically similar phenotypes [14]. These molecular signatures represent the most 
perturbed networks in tumor samples as compared to non-tumor samples. It is known that 
tumorigenesis is a multi-step and complicated process; different biological networks 
associated with glioma evolvement become affected at different time points [15, 16]. By 
identifying these networks, we enhance our understanding of astrocytoma development from 
a network-based context. 
Besides finding networks that could accurately predict histological grades of the patients, we 
also searched for networks that could predict survival. Among the four astrocytoma grades, 
high grades (HGA, include grade 3 and 4 tumors) have raised more interest than the other 
two grades, because of their sample availabilities and poor survival prospects [10, 11, 17]. 
Due to their molecular heterogeneity, these tumors could be classified further into smaller 
subtypes, either according to the path of progression (primary and secondary) or according to 
survival prospects (proneural, proliferative, mesenchymal). HGA usually occur de novo 
(primary), but may also progress from a lower grade (secondary) [18, 19]. Primary and 
secondary HGAs share similar morphologic features, and it has remained controversial 
whether they can be distinguished histologically [20]. Moreover, they are not clearly 
different in prognosis [19, 20]; this has led many to look for alternative subtypes showing 
survival differences. Philips et. al. classified HGA into either proneural (PN), mesenchymal 
or proliferative using a set of 35 genes. The PN subtype was shown to survive longer than 
non-PN subtypes [10, 11, 17].  
 
Using unsupervised hierarchical clustering, we found a network, named EPONFKB, which 
could efficiently distinguish HGA patients into two groups with significant survival 
difference (P = 2.4e-8), giving a much better separation between survival curves than when 
defined exclusively by histological grades (P = 2.2e-6). The prognostic value of the subtypes 
outperforms that based on primary/secondary subclasses (P = 0.001) and is comparable to 
PN/non-PN subclasses (P = 1.2e-8). 
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We defined the term “progression” following from the concept of secondary GBM, which 
has recurred in a patient with previously diagnosed lower grade astrocytoma. Since pilocytic 
tumors generally do not progress, the hypothetical sequence of progression is from normal to 
low-grade astrocytoma, progressing to anaplastic astrocytoma and eventually to GBM. The 
last part of our study was devoted to find progression-specific genes. From our datasets, two 
sets of genes that changed consistently in astrocytoma progression were identified and 
analyzed. One set consisted of 27 increasing genes and the other consisted of 19 decreasing 
genes, with both changing monotonically in the progressing sequence. These sets of genes 
allowed us to infer biological mechanisms as the tumor progresses. In doing so, we hope to 
provide genetic evidence associated with astrocytoma progression, which may help guide 
therapeutic decisions and eventually improve the clinical outcome. 
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CHAPTER 2 
RESULTS/DISCUSSION 
2.1 Effect of consensus preprocessing  
Direct integration of datasets generated by different platforms, institutions and experiments 
introduces noise into data and may lead to the discovery of false biomarkers, therefore 
appropriate pre-computation is a necessary step in all meta-analysis studies [21]. Our pre-
processing method greatly reduced sources of variations illustrated by an increase in Pearson 
correlation coefficients among patients. Figure 1a) is the Pearson correlation coefficient matrix 
obtained by applying GCRMA on raw microarray profiles of individual studies and combine 
them, and Figure 1b) was obtained by consensus pre-processing, which assembled raw 
expression data of 460 patients together and then applied necessary normalization steps (See 
Materials and Methods). 
 
In Figure 1, laboratory effects are still prominent; due to the differences in sample 
characteristics, sample preparation, hybridization, and other protocol differences, tumor samples 
from the same institution looked more homogenous than samples obtained from different 
institutions. However, with consensus processing, these disturbances were greatly alleviated with 
the average correlation coefficient increased from 0.87 (Figure 1) to 0.95 (Figure 2). 
 
Our processing method also allowed us to compute our confidence in whether a transcript is 
reliably present. We followed the probe sets detection algorithm implemented in Matlab 
Bioinformatics Toolbox (P-value for presence at 0.06, marginal at 0.04 and absence at P values 
below 0.04) and investigated how different probes filtering criteria (probes having 0%, or less 
than 25%, 50 %, 75% present calls for any phenotype could possibly be removed) affected the 
accuracy (Figure A.1) [22]. DIRAC showed robust performance against different numbers of 
probes present. Approximately 5000 probes that were absent throughout the whole phenotype 
were removed as this filtering strategy resulted in the best classification accuracy (Figure A.1). 
15371 probes were kept for further analysis. 
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2.2 Global regulation of networks across phenotypes 
 
Besides capturing how network expression patterns differ between phenotypes, DIRAC also 
provides quantitative measures (µ or rank conservation index) of how network rankings differ for 
a selected phenotype. If the combinatorial gene interactions in a specific network are quite 
similar among different patients, the network is considered tightly regulated within its phenotype. 
On the other hand, the network is considered loosely regulated if the ranks of network genes are 
greatly varied between samples of the same phenotype. Rank conservation index is a measure of 
the relative stability or consistency with which network rankings are maintained in a population 
[14]. 
 
Averaging rank conservation indices over all the networks provides a measure of global 
regulation in different phenotypes. For example, networks in normal patients samples are more 
highly conserved on average (0.962) than networks in pilocytic tumors (0.944), Similarly, 
network rankings in grade 2 to GBM samples matched the respective templates for 93.7% (µ= 
0.937), 93.3% (µ=0.933) and 91.7% (µ=0.917) of all pairwise orderings on average. In fact, the 
relative magnitude of average rank conservation indices has an inverse correlation with the 
malignancy of phenotypes. This trend suggests that the more aggressive diseases may have 
greater overall variation in network ranking among different samples. In normal or low-grade 
astrocytoma patients, most networks are still under tight regulation to maintain normal cellular 
functions, as the tumor develops, more cooperating oncogenes involved in tumorigenesis and 
growth mechanisms were activated, consequently more biological networks become increasingly 
disturbed. This deregulation increases with grades may contribute to its malignancy. Based on a 
one-way ANOVA, the estimated overall P-value for the ordering of phenotypes in Figure 3 is 
smaller than 0.001. 
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2.3 Top biomarkers from each classification 
Instead of searching for best gene or gene pairs, our study aimed to search for a set of related 
genes that could accurately distinguish similar disease phenotypes. Expression levels of genes 
were grouped into 248 human signaling networks, defined according to the BioCarta gene sets 
collection in the Molecular Signatures Database (MSigDB) [23]. Microarray expression data of 
any two phenotypes among five disease/control states were combined and classified by DIRAC. 
Average cross-validation accuracy of 10 classifications is 86% (leave-one-out cross-validation) 
(Figure 3).  Two other manually curated network databases, Biology Process under Gene 
Ontology (BP), containing 825 curated pathways and cancer modules (CM) containing 456 
modules (specifically related to cancer were also candidates for network database [23]. The 
average leave-one-out cross-validation accuracies of DIRAC on these two gene sets collections 
were 87.5% and 89.0% respectively (Figure 3). Biocarta gene sets were chosen for further 
analysis based on two criteria: the relationships of the genes in each network are clearly defined 
with available interaction information, and the gene sets are small in size for time-efficient 
analysis. 
Though different malignancies of astrocytomas are theoretically well defined by the WHO, 
drawing a distinction between them may be challenging based on histological grounds alone. 
Clinical and neuroradiologic features such as age, previous treatment often facilitate diagnosis 
and prognosis [17]; for instance, pilocytic astrocytomas are known for their high incidence in 
children and are associated with favorable prognoses [24], while infilatrating tumors of grade 2 
to GBM occur usually in adults and are related to short survival [25]. However, these factors 
could be insufficiently decisive factors in diagnosis.   
To select the best therapeutic decisions requires understanding of molecular alterations leading to 
tumor carcinogenesis and astrocytoma progression. Tissue microarrays have emerged as a 
popular tool for high throughput measurements of human genetic profiles, due to their ability to 
measure the tissue-specific protein expressions and identify possible treatment targets connected 
to the clinical outcome [26]. However, most of the microarray studies are focused on the high-
grades, especially glioblastoma [9]. A meta-analysis including all malignancies of astrocytoma 
with normal brain tissues taken as control is necessary to gain insights into early and late events 
in the brain tumor evolution. 
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Malignant phenotypes, including cancers, usually arise as a net effect of interactions among 
multiple genes within networks. DIRAC is a powerful classification method based on the relative 
expression values of participating genes within biological networks. Furthermore, it identifies 
and measures network-level perturbations from a completely novel perspective, namely by the 
“combinatorial comparisons” of network genes as opposed to increases or decreases alone [14].  
By accounting for these combinatorial interactions, we alleviated the signal-to-noise issues in 
disease-perturbed networks. DIRAC classified astrocytoma patients of different grades with each 
other and with normal samples with fairly high accuracy, with the majority of classifications 
between different phenotypes above 90% accurate except in cases among grade 2 to grade 4 
tumors (G2 vs. G3 60%, G2 vs. G4 72%, G3 vs. G4 81%). This may be partially due to their 
invasive nature, which resulted in these tumors possessing histological and biological 
characteristics of more than one grade, posing challenges in the assignment of the grades; 
another reason is the small sample size of G2 tumors, which causes a less accurate training 
model and therefore, decreased precision in making predictions using DIRAC. In general, 
adjacent grades were similar in expression profiles and resulted in lower accuracies in these 
cases while far-apart grades were easier to distinguish. 
 
The classification performance is also limited by other factors. One possible factor is the 
presence of the subtypes and/or outliers (atypical patients) within cancer tumor samples [11, 18]. 
Due to limited access to normal brain tissues, they were collected and defined in different ways 
and some degree of heterogeneity was introduced into the datasets inevitably. Other factors 
potentially affecting accuracies, e.g. the clinical variables such as ages and tumor locations of the 
patients, which should be controlled for a fair comparison, were not available in most cases. 
Using a permutation-based testing to assess the statistical significance of estimated network 
classification rates (see Materials and Methods), we found a total of 219 and 195 networks which 
significantly discriminated between expression profiles of G1 versus normal controls and G2 
versus normal controls respectively, while 211 and 217 networks were identified as robust 
signatures in distinguishing anaplastic astrocytoma and glioblastoma from controls (P < 0.05). 
Among these differentially expressed networks (DENs), we estimated that only 5~6% (between 
11-12 networks in each set) are likely to have been found by chance rather than based on true 
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differences between the phenotypes, as determined by the FDR (see Materials and Methods). 
The top ten networks in each case were shown in Table 1a) to 1d) 
These networks represented significant changes that occurred in astrocytoma transitions. They 
could be functionally grouped into biological processes related to gliomagenesis and 
development such as cell cycle regulation, apoptosis signal transduction and immune system 
response [27]. 
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2.4 Inferences from changes in network ranking 
Different tumors vs. normal brains 
 
Sixteen networks were more perturbed in early stage astrocytoma patients than in advanced 
stages as indicated by a decreased network ranking. Interestingly, these networks contain proto-
oncogenes and are linked to early or initiation events in astrocytoma progression. An example is 
the platelet-derived growth factor (PDGF) signaling pathway whose ranks among all networks 
decreased with malignancy grade (Table 1e). In response to various stress stimuli, the receptor 
tyrosine kinase PDGFR-α binds with its ligand PDGF-α, to stimulate various mitogenesis 
mechanisms [28]. The downstream molecules also in the PDGF signaling pathway include key 
players in the JAK-STAT and MAPK/ERK signaling pathways (JAK1, STAT1, STAT3, 
STAT5A and different isoforms of mitogen-activated protein (MAP) kinases, MAP2K1, 
MAP2K4, MAPK3, MAPK8). The PDGF signaling plays central roles during the initiation and 
progression of gliomas, and the overexpression of the receptors or the ligands has been found in 
both low/high astrocytomas [28-30]. The AKT pathway showed a similar pattern as the PDGF 
pathway in network ranking change, being more variably expressed in less malignant phenotypes 
(Table 1e); Phosphatidylinositol 3-kinases (PI3K) in the network converts phosphatidylinositol-
4, 5-bisphosphate (PIP2) to the second-messenger molecule PIP3, which in turn phosphorylates 
AKT protein. Phosphorylated AKT triggers downstream pathways through activation of 
mammalian target of rapamycin (mTOR), transcription factor NFk-β, and MDM2 [31]. This 
network not only stimulates growth but also contributes to an increase in anti-apoptotic features 
of glioma cells [27]. PDGF and its associated activated downstream AKT signaling, acting in 
concerted efforts to promote cellular growth and survival explain these networks being more 
disturbed in early stage astrocytomas; however, while the tumor cells are active in growth and 
neuronal differentiation, they have not yet acquired angiogenic properties as in the high grades 
[32]. As the tumor progresses to more advanced stages, these networks become less disturbed 
probably due to the angiogenesis related networks being more activated  
Six out of the sixteen networks are linked to immune system, one of the first responders in 
astrocytoma initiation. One such network, Cytokines and Inflammatory Response (INFLAM) 
showed similar expression pattern as the PDGF pathway (Table 1e). The network contains 8 
families of interleukins (IL), as well as the tumor necrosis factor (TNF), and all three isoforms of 
tumor growth factor (TGFβ). Cytokines like IL-1 and IL-6 are involved in a broad range of 
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different immune networks to provoke the inflammatory response; TNF is able to induce 
apoptotic cell death, stimulate inflammation, and inhibit tumorigenesis [33]; TGF-beta 
suppresses proliferation and differentiation of lymphocytes including cytolytic T cells, natural 
killer cells and macrophages, thus preventing immune surveillance of the developing tumor [34]. 
Various immune mechanisms communicate and coordinate their efforts to prevent tumor growth. 
The network being highly differentially expressed in pilocytic astrocytomas but less variably 
expressed at later stages supported the theory that the immune system is alerted at a relatively 
early stage of gliomagenesis and could potentially restrain the tumor growth. At more advanced 
stages, an immune response may still be active, but may possibly be immediately overwhelmed 
by high tumor burden and fail to show a highly variably expressed pattern [35].  
 
 In contrast, DIRAC captured an opposite ranking pattern for thirteen other networks. One of 
which is Cell to cell adhesion signaling (CELL2CELL) are related to the angiogenic properties 
of HGAs (Table 1e). This pathway contains major cell adhesion proteins like Catenin, PECAM-
1 and Paxillin. Catenins trigger changes in cell shape and motility; PECAM-1, involved in the 
formation of junctions between endothelial cells could modulate cell migration. Paxillin acts as 
an adaptor protein between proteins involved in adhesion signaling like FAK and SRC. These 
important molecules interact with cytoskeletal elements to produce changes in cell motility, 
migration, proliferation and shape [36]. Cell adhesion molecules have been associated with the 
invasive potential of GBMs, or a more aggressive subtype in GBM [11]. This network being 
more variably expressed in more malignant grades coincides with the fact that biological 
processes related to angiogenesis and cell invasion increase inactivity with aggressiveness of the 
tumor. 
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G1 vs other grades 
 
Pilocytic astrocytomas represent a distinct pathological and biological entity compared with 
other tumors [24]. They behave as well-circumscribed tumors which do not diffusely invade the 
brain parenchyma; instead, the tumor could be removed by surgery and recurrent rate is fairly 
low. However, there are no studies which compared pilocytic astrocytoma patients with normal 
as well as all other grades from a network perspective. Therefore, we are interested in finding the 
networks differentiating pilocytic astrocytoma from higher grades and inferring biological events 
to explain its antimigratory properties. We combined microarray samples of malignancy grade 2 
to grade 4 and termed this group collectively as diffusely infiltrating astrocytomas (DIA), 
indicating their nature to diffuse and spread. DIRAC detected 163 networks which could 
effectively separate grade 1 tumors from the rest (P<0.05) with their apparent accuracy ranging 
from 95% to 68%. The best network classifiers (with classification rate > 90%) are listed in 
Table 1f).  
 
 Among the best five classifiers, four of them are related to cell cycle regulation (Mechanism of 
Gene Regulation by Peroxisome Proliferator-activated receptors (alpha) (PPAR), Cell Cycle: 
G1/S Check Point (G1), Cell Cycle: G2/M Checkpoint (G2), p53 Signaling Pathway (P53)). A 
lot of genes are shared among these networks implying extensive overlaps among, and cross-talk 
between, these pathways. PPAR agonists affect expression of cell cycle related proteins in cell 
lines of glial brain tumors; they decrease cell proliferation, stimulate apoptosis and induce 
morphological changes and expression of markers associated with better prognosis [37]. P53 is a 
guardian in G1/S phase, whose inactivation allows cell cycle progression and makes apoptosis 
mechanisms ineffective. This tumor suppressor was shown to be not involved in the oncogenesis 
of pilocytic astrocytomas [24]; but for diffuse astrocytomas of WHO grade II, frequent mutation 
(occurs in up to 82%) of TP53, which encodes the protein was detected and believed to be one of 
its defining characteristics [16]. These networks also contain proto-oncogenes MDM2, which is a 
negative regulator of p53, members of the cyclin-dependent kinase (CDK) family (CDK2, CDK4 
etc.), and their inhibitors (CDKN 1A, CDKN 2A etc.). Similar to TP53, homozygous deletion of 
CDKN2A is found of 20% in diffuse astrocytoma while remains intact in grade 1 tumors [24], 
indicating these changes represent genetic events occurred to grade 2 or higher grade tumors. 
Altered combinatorial interactions among gene pairs in the cell cycle regulation networks in 
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pilocytic astrocytomas as compared to DIAs may contribute to effective tumor suppression 
mechanisms such as cell-cycle arrest, which eventually results in controlled tumor cell growth 
and less tendency to migrate to brain parenchyma than other grades. 
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2.5 Monotonically changing genes in astrocytoma progression 
Certain genes appeared to be repeatedly differentially expressed as we compared different tumor 
grades against controls; this led us to search for a list of genes whose expression level were 
consistently up or down regulated in human astrocytoma progression. In doing so, we hope to 
correlate the molecular changes with the histopathological development. The commonly 
recognized path of progression on a normal person starts with the onset of low-grade 
astrocytoma, skipping the first grade, progressing to anaplastic astrocytomas and eventually to 
GBM, though patients may not necessarily go through each stage. However, this model could 
hardly be proven clinically due to the lack of available tissues in the early phases of 
tumorigenesis. In this aspect, spontaneous genetically engineered mouse models provide an 
opportunity to track the molecular and pathological changes as a function of time. Low-grade 
astrocytoma started to develop as early as from 1-week old genetically engineered mouse; from 3 
to 8 weeks the incidence of low-grade astrocytomas progressively increased, with 85% of 12-
week-old mice harboring low or high-grade astorcytomas [38].  
 “Progression” in human astrocytomas was established as mentioned before, with the support of 
mouse models. We kept track of differentially expressed genes from normal to GBM and found 
27 genes that successively increased and 19 genes that similarly decreased their relative 
expression values. Considering both our increasing and decreasing genes, we grouped them into 
four functional categories according to in DNA damage repair, chromatin regulation and 
apoptosis (Table A.1-2), according to the putative functions they encode.  
DNA Damage Repair related genes 
Our list of successively changing genes includes several genes that play critical roles in specific 
DNA damage repair processes. Those genes include DCLRE1B, PALB2, RBBP8, TOP1 and 
SMARCA2; all of these, with the exception of SMARCA2, increased their relative expressions 
in astrocytoma progression (Table A.1-2). The susceptibility to DNA damage arises from a 
compromised repair system, either in the repair proteins themselves or in the DNA damage 
response pathways. Genomic instability and the susceptibility to DNA damage can be indicative 
of a poor prognosis in many cancers, including gliomas.  
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DCLRE1B, also known as Apollo, is a 5’ to 3’ exonuclease that helps to maintain the 3’ 
overhang of telomeres, thereby suppressing activation of the DNA damage sensing protein [39]. 
Along with its binding partner TRF2, Apollo was also reported to help relieving topological 
stress during telomere replication in S phase and protecting chromosome termini from being 
recognized and processed as DNA damage [40, 41]. Increased levels of Apollo thus may repress 
the activation of DNA-damage or apoptosis mechanisms in astrocytoma progression. 
Apollo negatively regulates Topoisomerase 1 (TOP1) [42], another upregulating gene that 
controls and overcomes topological problems during DNA transcription. It was implicated in all 
three functional classes, but it has been mostly associated with DNA damage repair [43-45]. 
Inhibitors of TOP1 have shown promising activity in patients with high grade gliomas and 
warrant further study [46].  
TOP1 was also regulated by RBBP8 in our list, commonly known as CtIP, which functions in 
DNA double strand break repair by homologous recombination [42, 47, 48]. It has also been 
characterized as a transcriptional cofactor, interacting with and modulating the activity of the 
transcriptional repressor CtBP [49], the DNA repair protein BRCA1[50, 51], and G1/S-specific 
protein CyclinD1 as well as the oncogene retinoblastoma (Rb) [52, 53]. Due to its association 
with BRCA1, it had been heavily studied in breast cancer, with the corresponding protein 
expression considered as useful biomarkers for breast cancer prognosis; in addition, CtIP 
silencing was reported to be a novel mechanism for effective breast cancer therapy [54]. Another 
increasing gene, PALB2, last one in this category, enables recombinational DNA repair, in ways 
similar to RBBP8, through binding with BRCA2 [55].  Its increase in activity may imply its roles 
in cell cycle progression leading to tumor cell proliferation, in addition to preventing apoptosis 
of tumor cells in astrocytoma progression. 
Chromatin remodeling related genes 
All of the human genome is packaged into chromatin, which is continuously remodeled. The fate 
of the cell relies on a delicate balance between gene expression and repression. The 
transcriptional control of the genome is maintained not only by transcription factors but also 
chromatin remodeling proteins [56]. 4 increasing genes (PRMT1, ENY2, ESPL1, NCAPG 
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WDR76) and one decreasing gene SMARCA2 identified in our list, displayed significant 
connections to the chromatin modification process, as listed in Table A.1-2. 
The building blocks of chromatin, named the nucleosome, can be restructured by two 
mechanisms: 1. the movement of nucleosomes by ATP-dependent chromatin remodeling 
complexes; and 2. the modification of core histones by histone acetyltransferases, deactylases, 
methyltrans-ferases, and kinases [56, 57]. Our gene set modified the chromatin through both 
mechanisms. 
As an arginine-specific histone methyltransferase, PRMT5 is primarily known to be involved in 
epigenetic gene regulation through histone methylation of H2A, H3 and H4 [58, 59]. It also has 
the ability to facilitate dedifferentiation and to create pluripotent stem cells, resembles functions 
of biomarkers indicative of mesenchymal high grade glioma (HGA), a more malignant subtype 
associates with worse prognosis. 
PRMT5 also methylates several other important glioma-related genes including p53, JAK2 and 
EGFR. By interacting with PRMT, p53, a tumor suppressor, was weakened in its target 
specificity and ability to facilitate DNA damage repair [60-62]; PRMT5 has also been linked to 
the invasive and migratory potential of glioblastoma cells through its regulation of the 
ubiquitously expressed tyrosine kinase JAK2 [63]. Further extending PRMT5’s role in 
oncogenesis is the observation that activation of the JAK2/STAT3 pathway correlates with 
glioma grade and aggressiveness, and that this activation occurs more frequently in gliomas 
expressed with EFGR, another reported PRMT5 methylation target [64]. Taken together, 
increased expression of PRMT5 may directly or indirectly contribute to a cascade of events that 
lead to the progression of early-grade tumors to later more malignant phenotypes. 
SMARCA2, better known as Brm, is a ATP-dependent chromatin complex. Consistent with our 
observation that Brm monotonically decreased with respect to glioma grade, aberrant expression 
of Brm genes is associated with disease development and progression in many cancers [65, 66]. 
Though the exact mechanism is not clear, there has been speculation that the loss of Brm may 
result in the increased interactions with transcription factors such as Oct4 and Sox2 to enable 
pluripotency, which leads to tumor cell proliferation and  [67-69].  Lastly, Brm is also known to 
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interact with PRMT5 resulting in further chromatin remodeling through the methylating action of 
PRMT5 on H3 and H4 [70].   
The remaining two genes ENY2 and ESPL1, were also implicated in regulation of gene 
expression. ENY2 has been identified as a part of another chromatin remodeling complex, 
SAGA, known for its ability to acetylate histones H2A and H2B [71]; On the other hand, ESPL1 
plays a pivotal role in the separation of sister chromatids at anaphase. Overexpression and 
mislocalization of ESPL1 were seen in a wide range of human cancers [72] .  
Apoptosis 
Many genes in our list encoded apoptotic proteins. Unlike the other two functional categories, 
the majority of apoptotic genes (6 out of 10) decreased with tumor grade (Table A.1-2). Because 
evasion of apoptosis is generally considered as a hallmark of cancer, pro-apoptotic genes that 
suppress formation of tumors should decrease their expression with tumor grade, for instance 
C10orf97 and DSTYK. In contrast, anti-apoptotic genes that facilitate tumorigenesis should be 
more active in high-grade gliomas, as in the case of NUP107.  However, we also found AK2 and 
BCL2L11 who seemed to induce cell death, became more active as the tumor progressed; to 
support our finding. a number of studies validated their overexpression in various diseases, 
including cancer,  
One possible explanation to this interesting phenomenon is that genes and their respective 
encoded proteins usually play a number of roles in signal transduction, and apoptosis may be one 
of the many functions known to us, therefore the up or down regulation of a certain transcript is a 
net effect of biological pathways interacting and influencing each other rather. We will need 
more discoveries regarding their exact roles in cancer, or astrocytoma in particular. Nevertheless, 
a large number of genes related to programmed cell death, allowed us to further understand its 
involvement in glioma development and progression. 
Blood biomarkers 
 
Four of the key transcripts (ESPL1, KIF15, NUP205, PRMT5) in this list encoded proteins that 
are secreted into the blood. These blood biomarkers have significant potential applications in 
early detection and management of various diseases, including cancer. Simply by measuring 
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altered blood levels of proteins without the need to sample disease tissues is a less expensive and 
more friendly therapeutic option for disease prediction and monitoring than traditional medicine. 
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2.6 Prognostic networks that reclassifies high grade astrocytoma 
HGAs are very aggressive tumors usually associated with worst prognosis, with average length 
of survival for G3 patients around three years, and fourteen months for GBM patients [73]. Due 
to the heterogeneity of their molecular profiles, a lot of efforts had been devoted to discover 
subtypes within the large collection of tumor samples. A long-existing attempt to classify HGA 
is according to the clinical histories of patients: a HGA tumor may be classified as either primary 
if there was no prior history of tumor occurrence, or secondary, if the tumor recurred to the 
patients, usually in a more malignant form. Primary tumors are believed to occur to older 
patients, and have a slightly shorter survival time [18]. 
Another relatively new approach by Phillips et al, utilized a set of 35 genes to classify HGAs 
into three classes, and resembled each subclass with a corresponding stage in neurogenesis .  One 
tumor class (proneural or PN) displaying neuronal lineage markers shows longer survival, while 
two other tumor classes enriched for neural stem cell markers display equally short survival 
(non-proneural or non-PN).  
Our study was also interested in finding biomarkers indicative of HGA prognosis. With available 
survival information from 239 patients, we derived a novel network with significant prognostic 
value. Using a distance matrix defined based on the DIRAC metric (see Materials and 
Methods), the genomic profiles of all HGA patients were grouped into two clusters using 
unsupervised clustering. Subsequent log-rank tests on the survival estimates of these two groups 
gave a P-value of 2.4e-8, comparable to the performance given by the genes separating proneural 
vs, non-proneural groups (P value=1.2e-8); more importantly, it outperforms p-values given by 
histological separation (grade 3 against grade 4 tumors, P value=0.001) as well as by path of 
progression (primary against secondary tumors, P value=2.2e-6). Besides this network, four 
others defined in the Biocarta network collection yielded statistically significant P values in their 
respective log-rank tests (Table A.3) 
The EPONFKB network utilizes erythropoietin to mediate neuroprotection through NF-kB. It 
initiates signaling when erythropoietin (EPO) binds with its receptor EPOR to trigger NF-kappa-
B, a heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65 and 
NFKB1/p50 in the presence of Janus kinase 2 (JAK2). The activated complex then translocates 
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to the nucleus and subsequently sends out both apoptotic signals through superoxide dismutase 2 
(SOD2) and antiapoptotic signals through glutamate receptor subunit zeta-1 (GRIN1).  
Involvement of the EPONFKB network in gliomas is an interesting and debatable subject as how 
it affects survival.  The standard treatment of GBM with radiation does significant damage to the 
surrounding brain, resulting in significant collateral damage.  This damage is often referred to as 
“radiochemobrain” and results in slowing psychomotor skills, cognitive decline, fatigue, and loss 
of drive, all of which significantly reduced quality of life [74, 75]. To counteract these effects, 
patients have been given hematopoetic growth factor erythropoietin prior to and following 
radiation. EPO signaling crossactivates the antiapoptotic transcription factor NF-kappaB, this 
causes neuroprotection against oxidative stress and implies radioprotection. As a matter of fact, 
EPO has pleotrophic affects on the brain including anti-apoptotic, antioxidative, neurotrophic, 
axon-protective, angiogenic, and neurogenic – many of which appear to be neuroprotective for 
the insults of radiation and chemotherapy [76-82]. In addition, EPO has also been shown to 
improve the responsiveness of tumors to radiation therapy in human glioma xenographs by 
increasing tumor oxygenation [83, 84].   
Despite all the positive effects EPO it believed to have, these same effects could also help to 
promote tumor growth. Administering EPO as part of chemotherapy is controversial because of 
the possibility for it to promote tumor growth [85-88]. Recently, EPO signaling was shown to be 
involved in angiogenesis of human glioma cells as well as cancer stem cell maintenance [89, 90]. 
Still, others have shown that while EPO does augment the survival of glioma cells, it is unlikely 
to appreciably influence basal glioma growth [91]. 
While our results implicate the EPONFKB as a novel and powerful biomarker in predicting 
patient survival, the exact mechanism through it modulates survival is unclear. One possible 
explanation is the longer survival subtype with 161 patients may have more patients underwent 
EPO-related chemotherapy; this group also has a larger proportion of patients (45%) belonged to 
the PN subtype, as compared to the shorter survival subtype (13%), consistent with the 
observation that PN class has better prognosis than non-PN classes.  
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2.7 Tables 
Network Name Apparent 
Accuracy 
P-values 
G2 0.984 <0.001 
G1 0.984 <0.001 
TID 0.977 <0.001 
PDGF 0.977 <0.001 
EGF 0.977 <0.001 
IL1R 0.977 <0.001 
P38MAPK 0.977 <0.001 
GSK3 0.974 <0.001 
HIVNEF 0.974 <0.001 
EIF4 0.973 <0.001 
Table 1. Top 10 networks differentiating normal from grade 1 patients 
Network Name Apparent 
Accuracy 
P-values 
PROTEASOME 0.982 <0.001 
EGF 0.982 <0.001 
MCALPAIN 0.964 <0.001 
ALK 0.964 <0.001 
CBL 0.949 <0.001 
GSK3 0.949 <0.001 
PDGF 0.948 <0.001 
AT1R 0.946 <0.001 
EIF4 0.941 <0.001 
FAS 0.940 <0.001 
Table 2. Top 10 networks differentiating normal from grade 2 patients 
Network Name Apparent 
Accuracy 
P-values 
ERK 0.991 <0.001 
CHEMICAL 0.955 <0.001 
EGF 0.954 <0.001 
MCALPAIN 0.954 <0.001 
KERATINOCYTE 0.945 <0.001 
IGF1MTOR 0.944 <0.001 
CBL 0.935 <0.001 
BCR 0.935 <0.001 
GSK3 0.935 <0.001 
IL2RB 0.934 <0.001 
Table 3. Top 10 networks differentiating normal from grade 3 patients 
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Network Name Apparent 
Accuracy 
P-values 
CELL2CELL 0.962 <0.001 
P38MAPK 0.950 <0.001 
G2 0.949 <0.001 
G1 0.948 <0.001 
ERK 0.947 <0.001 
MPR 0.943 <0.001 
PROTEASOME 0.936 <0.001 
VEGF 0.935 <0.001 
CELLCYCLE 0.934 <0.001 
HIVNEF 0.934 <0.001 
Table 4. Top 10 networks differentiating normal from grade 4 patients 
 
 
Table 5. Changes in network rankings of selected networks in different astrocytoma grades 
vs. normal controls; PDGF, AKT and INFLAM showed decreased ranking as the diseases 
develop, while CELL2CELL showed an opposite pattern 
 
 
 
 
 
 
 
Table 6. Top 5 networks differentiating grade 1 from other astrocytoma tumors 
 
 
 G1 G2 G3 G4 
Ranki
ng 
Classificat
ion Rate 
FD
R 
Rank
ing 
Classifica
tion Rate 
FD
R 
Rank
ing 
Classifica
tion Rate 
FD
R 
Rank
ing 
Classifica
tion Rate 
FD
R 
PDGF 4 0.977 0 7 0.948 0 32 0.899 0 66 0.894 0 
AKT 65 0.939 0 122 0.840 0.0
008 
141 0.810 0.0
000
1 
151 0.824 0 
INFLA
M 
73 0.935 0 99 0.862 0.0
002 
107 0.851 0 155 0.821 0 
CELL2
CELL 
116 0.908 0 81 0.871 0.0
002 
65 0.873 0 1 0.962 0 
Network Name Apparent 
Accuracy 
FDR 
PPARA 0.946 0 
G2 0.932 0 
KERATINOCYTE 0.926 0 
P53 0.915 0 
G1 0.911 0 
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Table 7.  Summary of microarray expression datasets included in the study 
aOne normal fetal brain RNA, 1 normal cerebellum RNA, 2 normal tissue were surgically 
removed tissue adjacent to resected tumor tissue and RNA extracted 
b Brain samples of epilepsy patients 
c Pooled normal brain tissue 
 
 
 
 
 
 
Platform Authors of Study 
(year, GSE 
accession) 
Number of patients in each class 
Normal Grade 1 Grade 2 Grade 3 Grade 4 
U133A Frejie et al (2006, 
GSE 4412) [10] 
0 0 0 8 46 
Phillips et al (2006, 
GSE 4271) [11] 
0 0 0 21 55 
Wong et al (2008,  
GSE 12907) [12] 
4a 21 0 0 0 
Rich et al (2005, 
GSE 13041) [38] 
0 0 0 0 31 
Lee et al (2008, 
GSE 13041) [17] 
0 0 0 0 28 
Barrow et al (2008, 
GSE 13041) [17] 
0 0 0 0 31 
 Mcdonald et al 
(2005, GSE 3185) 
0 0 3 0 0 
Total U133A 4  21  3  29  191  
U133- 
Plus 2.0 
Sun et al (2006, 
GSE 4290) [13] 
23b 0 7 19 77 
Liu et al (2010, 
GSE 19728)  
1c 
 
2 5 5 5 
Sharma et al (2007,  
GSE5675) [39] 
0 41 0 0 0 
Lee et al (2008, 
GSE 13041) [17] 
0 0 0 0 27 
Total U133-Plus 2.0 24 43 12 24 109 
Total  28  64  15  53  300  
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2.8 Figures 
  
Figure 1. Pearson-correlation matrix before consensus pre-processing. Tumor samples from 
the same experiments displayed higher homogeneity than other samples 
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 Figure 2: Pearson-correlation after consensus pre-processing; Laboratory effects are much 
less obvious; tumor samples from different studies or phenotypes all look highly correlated. 
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Figure 3: Rank conservation of networks across phenotypes. Colors on the heatmap represent 
rank conservation indices for each network in the five different phenotypes, where the brighter 
colors indicate very tight regulation of network ranking in a phenotype and the darker colors 
indicate loose regulation of networks. 
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Figure 4: Classification accuracy on different network databases; cross-validation accuracies 
of DIRAC using three different network collections are fairly close 
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Figure 5: Genes showing consistent dys-regulation in progression a) 27 upregulated genes b)  
19 downregulated genes 
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Figure 6: Comparison of different approaches to re-classify HGAs.  a) Survival estimates of 
two groups separated by histological grades b) by primary or secondary HGA subtype c) by 
prognostic network marker EPONFKB d) by proneural (PN) or non-PN subtype. The log-rank 
test on the two subtypes defined by our network marker has a p-value comparable to one of the 
best regarding scheme. 
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CHAPTER 3 
CONCLUSIONS 
DIRAC is a classification approach accounted for the combinatorial behavior of interacting 
genes in biological networks, which provides accurate molecular signatures between different 
astrocytoma grades. These signatures allowed us to learn the most disturbed networks associated 
with tumor malignancy. Moreover, a network consisted of 11 individual genes was found to be 
significant in predicting prognosis of high grade astrocytomas.  Besides network biomarkers, 46 
genes were observed to change their expression values in a unidirectional manner with the tumor 
grade; their biological functions and implications in astrocytoma progression were identified. 
  
The significantly perturbed pathways identified in this study offered biological insights into 
tumorigenesis and progression of astrocytoma, and may be potential candidates for novel 
diagnostic approaches. Due to the high heterogeneity of malignant brain tumors, the ideal and 
most effective therapy should be treatment personalized for each individual patient. Clinical 
therapies could be developed based on assessing the differentially expressed signaling networks, 
and targeting of specific network alone or in combination with traditional therapy.  
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CHAPTER 4 
MATERIALS AND METHODS 
4.1 Collection of microarray data 
Raw microarray CEL files (Affymetrix, Santa Clara, CA) were retrieved from previous studies 
deposited to the publicly accessible microarray database, the NCBI Gene Expression Omnibus 
(GEO) between year 2005 and 2010. The data selection criterion is that the RNA of the tumor 
samples had to be hybridized to either one of the two platforms, Affymatrix HG-U133A or its 
complimentary version, HG-U133-plus 2 GeneChips. Affymatrix HG-U133B was not chosen 
since it does not include any probes common with U133A; this mutual exclusiveness of probes 
would add heterogeneity into the data, which would increase noise in separating different 
phenotypes. The GEO accession number, year of publication, together with number and grades 
of samples reported in each original study are listed in Table 7. 
4.2 Integration of microarray data 
A unique “consensus preprocessing” method was used on microarray CEL files to normalize 
differences introduced by different studies and individual preprocessing methods. Common 
probes (22277 probes) shared by two microarray chips (U133A and U133-Plus 2.0) were 
identified according to publicly available array descriptions, followed by GeneChip RMA 
(GCRMA) with the default settings from Matlab (MATLAB version 7.7, The MathWorks Inc., 
2008). GCRMA was selected because its performance was observed to be superior to RMA and 
other normalizations for background adjustment of multi-arrays on the unified gene expression 
matrix [22].   
In order to convert the probe intensity matrix to a gene expression matrix, the probe set lists were 
annotated according to definitions of these Affymatrix GeneChips. Probes mapping to multiple 
genes were removed from the probe lists; in cases where multiple probes correspond to the same 
gene, the maximum intensity was computed to determine the corresponding expression value for 
that gene.  In the last step of preprocessing, all absolute intensity values were replaced by their 
relative ranks within each array. 
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4.3 Classification using DIRAC 
 
Networks consist of components (nodes) and interactions (edges) between them. The nodes 
could be metabolites and macromolecules such as proteins, RNA molecules and gene sequences, 
while the edges are physical, biochemical and functional interactions. Our study considered three 
manually curated gene sets (BIOCARTA, Cancer Module and GO-BP) collected from various 
sources such as online pathway databases, publications in PubMed, and knowledge of domain 
experts [40].  
For each selected network, DIRAC computes the expected ranking of network genes (rank 
template) by averaging the individual ordered gene expression profile within each phenotype, 
and measures how closely each sample’s network ordering matches the phenotype-specific 
template (rank matching score). Class labels were assigned based on similarity of the patient’s 
individual profile to one particular template of the two templates, and apparent accuracy was 
calculated based on percentage of correct prediction of phenotypes; the estimated classification 
accuracies for all networks were calculated likewise [14]. A null-distribution of network 
classification rates were generated by randomly reassigning the original phenotype labels 1000 
times. A significance level was measured as the probability of observing classification rates in 
the null distribution greater than or equal to the real rates. To address the issue of multiple-
hypothesis testing, the significance level was adjusted to false discovery rate (FDR), representing 
the fraction of expected false positives [14].  
 
We used leave-one-out cross validation to estimate the error rate of DIRAC. Importantly, all 
processes including defining rank templates, and selecting the best network were done within 
cross-validation, using only the training samples (i.e., no information from test samples were 
used to train classifiers) [14]. The overall cross validation classification rate was calculated from 
the average of sensitivity and specificity of all predictions in each set. 
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4.4 Rank conservation indices 
The rank template for each phenotype and rank matching scores of each patient to the template 
were calculated as explained earlier (for details, please refer to [14]). The rank conservation 
index is the average of the all matching scores of samples within a certain phenotype. By 
averaging the rank conservation indices of all networks for a disease, we had a single value 
measuring the relative deregulation of the networks for that phenotype. 
 
4.5 Monotonically increasing/decreasing genes 
In each adjacent pair of astrocytoma grades in the progression sequence, differentially expressed 
genes (DEGs) were selected based on the Wilcoxon ranksum test (P < 0.05 after Bonferroni 
correction). The intersection of these gene sets represented consistently deregulated genes. 27 
DEGs showed consistently positive log2 expression ratios in each gene set and thus are the 
monotonically increasing genes in progression, while another 19 decreased their expression as 
the disease progresses.  
 
4.6 Subtyping HGA 
Time of survival (days or weeks) and subtype designations were available for 239 patients. The 
microarray expression matrix of this subset of patients was normalized as previously described. 
A distance matrix was constructed for each selected network based on the pairwise orderings of 
the genes within the network. For example, if a network P consisted of six genes, there could be 
( ) 1562 = distinct ordered pairs. For a gene pair i and j, let X denote their corresponding expression 
values. If Xi<Xj or Xi>Xj for both patient A and B, the distance of these two patients was 0; 
otherwise the distance was 1. We summed up the distances for all 15 possible comparisons and 
recorded it as the total distance of patients A and B on network P. This procedure was repeated 
for all patients to get a 239 × 239 distance matrix. 
Hierarchical clustering in MATLAB was used to group the patients into two groups (linkage 
method: weighted average distance, Figure A.2). The two largest branches were considered first; 
each group must have more than 10% of all samples (24 for this case) to be called a subtype, 
otherwise these samples are considered as outliers and the next largest group is taken as a 
possible subtype.  
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After two groups with reasonable sizes were determined, the Kaplan-Meier method was used to 
estimate the survival distributions. Log-rank tests were used to test the difference between 
survival groups. 
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APPENDIX 
 
Figure A.1: Effect of filtering genes on accuracy. Average accuracies of 10 individual 
classifications by DIRAC do not vary significantly with number of genes present. 
 
Figure A.2: Hierarchical clustering of HGA tumors. Two distinct clusters are formed; the 
distance matrix is defined by gene pair ordering matches in EPONFKB network.  
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Table A.1 
Gene Name Full Name/Atlas Encoded protein function and association 
with cancer 
AHCY adenosylhomocysteinase Hydrolase,  
upregulated in colorectal cancer 
AK2 adenylate kinase 2 Induces apoptosis, upregulated in  epilepsy 
patients 
BCL2L11 BCL2-like 11/BIM Induces apoptosis, upregulated in cancer cells 
CANX calnexin Apoptosis and protein folding 
DCLRE1B DNA cross-link repair 1B/ 
APOLLO 
DNA damage repair 
ENY2 enhancer of yellow 2 Chromatin regulation 
ESPL1 extra spindle pole bodies 
homolog 1 
Chromatin regulation  
Oncogene, overexpressed in breast, prostate 
cancers and osteosarcoma. 
GBE1 glucan (1,4-alpha-), 
branching enzyme 1 
glycogen branching enzyme 
GEMIN4 gem associated protein 4 part of a complex functioning in spliceosomal 
snRNP assembly in the cytoplasm 
GNPAT glyceronephosphate O-
acyltransferase 
essential to the synthesis of ether phospholipids; 
implicated in  schizophrenia 
GRM8 glutamate receptor, 
metabotropic 8 
G protein-coupled receptors for excitatory 
neurotransmitter 
inhibition of the cyclic AMP cascade 
implicated in  schizophrenia 
KIF15 kinesin family member 15 neuronal development 
NCAPG non-SMC condensin I 
complex, subunit G 
chromatin regulation 
 
NUP107 nucleoporin 107kDa Depletion induces apoptosis 
NUP205 nucleoporin 205kDa Essential component of nuclear pore complex 
PALB2 partner and localizer of 
BRCA2 
DNA damage repair 
PDIA6 protein disulfide isomerase 
family A, member 6 
folding of disulfide-bonded proteins, a 
biomarker for prostate cancer 
PMS2L11 postmeiotic segregation 
increased 2 pseudogene 11 
unknown function 
PRMT5 protein arginine 
methyltransferase 5 
chromatin remodeling 
RBBP8 retinoblastoma binding 
protein 8/ CtIP 
DNA damage repair 
RSRC1 arginine/serine-rich coiled-
coil 1 
participate in multiple steps of mRNA splicing, 
implicated in  schizophrenia 
TFR2 transferrin receptor 2 involved in iron 
    metabolism, hepatocyte function and 
erythrocyte differentiation 
TMEM194A transmembrane protein unknown function 
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Table A.1, name and functions of 27 monotonically increasing transcripts 
 
Table A.2 
Gene Name Full Name/Atlas Encoded protein function and association 
with cancer 
AAK1 AP2 associated kinase 1 Regulation of clathrin-mediated endocytosis 
ACSL4 acyl-CoA synthetase long-
chain family member 4 
Axonal transport 
Blocks apoptosis and promotes carcinogenesis 
API5 apoptosis inhibitor 5 Inhibits apoptosis 
C10orf97 chromosome-10, open 
reading frame-97 
Pro-apoptosis, tumor-suppressor 
C6orf211 chromosome 6 open 
reading frame 211 
Unknown function 
DSTYK dual serine/threonine and 
tyrosine protein kinase 
Induce apoptosis 
GNAO1 guanine nucleotide binding 
protein (G protein), alpha 
activating activity 
polypeptide O 
Regulation of cAMP levels 
Implicated in schizophrenia 
ITM2B integral membrane protein 
2B 
Induce apoptosis 
NDUFB8 NADH dehydrogenase 
(ubiquinone) 1 beta 
subcomplex, 8, 
Accessory subunit of the mitochondrial 
membrane respiratory chain NADH 
dehydrogenase 
NMT2 N-myristoyltransferase 2 Depletion induced apoptosis 
PRNP prion protein neuronal development and synaptic plasticity, 
implicated in neurodegenerative diseases 
RAB33B RAB33B, member RAS 
oncogene family 
Protein transport 
RNF11 ring finger protein 11 May play a role in inflammatory pathways 
SACM1L SAC1 suppressor of actin 
mutations 1-like 
Hydrolase 
 
SDCCAG1 Serologically defined colon 
cancer antigen 1 
Plays a role in nuclear export 
SMARCA2 SWI/SNF related, matrix 
associated, actin dependent 
regulator of chromatin, 
Chromatin regulation 
DNA damage repair 
 
194A 
TMEM45A transmembrane protein 
45A 
unknown function 
TOP1 topoisomerase (DNA) I DNA damage repair 
WDR76 WD repeat domain 76 Unknown function 
ZNF282 zinc finger protein 282 Binds to a repressive element of the human T 
cell leukemia 
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subfamily a, member 
2/BRM 
 
STRN3 striatin, calmodulin binding 
protein 3 
scaffolding or signaling 
THOC7 THO complex 7 homolog mRNA export 
USP12 ubiquitin specific peptidase 
12 
Deubiquitinating enzyme, associated with 
Parkinson’s disease 
Table A.2, name and functions of 19 monotonically decreasing transcript 
 
Network Name P-value 
EPONFKB  2.5*10-8  
CARDIACEGF  2.7*10-5  
IL22BP  4.5*10-5  
EPO 4.6*10-5 
FIBRINOLYSIS  5.3*10-5  
 
Table A.3: Networks that significantly differentiate 239 HGA patients into two groups with 
survival difference. These networks are arranged in decreasing p-values; the most significant 
EPONFKB outperform histological grade; the others did not but still significant) 
 
